Jun 10, 2026 – 3.35pmMelbourne’s Vitrafy Life Sciences, a biomedical cryopreservation business that listed on the ASX in late 2024, sent out three brokers to hunt for up to $32 million on Wednesday.Vitrafy co-founders Sean Cameron and Brent Owens. Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones.Kanika Sood is a journalist based in Sydney who writes for the Street Talk column.Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review.Subscribe to gift this articleGift 5 articles to anyone you choose each month when you subscribe.Subscribe nowAlready a subscriber?
Vitrafy Life Sciences seeks up to $32m in cash call
A presentation shown to potential investors highlighted its exposure to the US blood platelet industry, saying a US Army study had validated 94 per cent post-thawing recovery.
133 words~1 min read
